

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/552,641	. 10/07/2005	Russell Gene Higuchi	21634-US2	1928
22829 7590 07/18/2007 ROCHE MOLECULAR SYSTEMS INC PATENT LAW DEPARTMENT			EXAMINER	
			BAUSCH, SARAE L	
1145 ATLANTIC AVENUE ALAMEDA, CA 94501		•	ART UNIT	PAPER NUMBER
· ·			1634	
			MAIL DATE	DELIVERY MODE
		•	07/18/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)		
	10/552,641	HIGUCHI ET AL.		
Office Action Summary	Examiner	Art Unit		
	Sarae Bausch	1634		
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address		
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period where the provision of the period for reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed on 07 Oc	action is non-final. nce except for formal matters, pro			
Disposition of Claims				
4) Claim(s) 1-78 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-78 are subject to restriction and/or expressions.	vn from consideration.			
Application Papers		•		
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the of Replacement drawing sheet(s) including the correction of the order	epted or b) objected to by the I drawing(s) be held in abeyance. Sec ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).		
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicati ity documents have been receive ı (PCT Rule 17.2(a)).	on No ed in this National Stage		
Attachment(s) 1) Notice of References Cited (PTO-892) (2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08)	4)	ate		
Paper No(s)/Mail Date 6) Other:				

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-51, drawn to method of identifying a polymorphism.

Group II, claim(s) 52-68, drawn to nucleic acid.

Group III, claim(s) 78, drawn to a system.

2. The inventions listed as Groups I-V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature of Group I is considered to be the frizzled-related protein gene. Schemann et al. (Cardiovascular Research, 45 (2000), pp.720-728, cited on IDS) teach expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium (see figure 1). Thus, the technical feature linking the recited groups I-III does not constitute a special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art.

Further Restriction Requirement

Additionally, group I and II named above is subject to further restriction. Applicant is required to further elect a specific polymorphism or combination of polymorphisms. This is NOT an election of species.

The claims are drawn to methods which require identifying at least one polymorphism in a nucleic acid sample to determine obesity or osteoporosis. The claims are directed to numerous distinct methods recited in the alternative. The language "at least one polymorphism" and "at least two or more polymorphism" requires that one, two, three or any number more up to the 15 recited polymorphisms are detected within a target nucleic acid sample. For example, a method requiring T allele of T2303723C is distinct from a method requiring A allele of G19524A because the methods have a different mode of operation, do not overlap in scope, and they are not obvious variants of one another (see MPEP 806.05(j)). As seen in Table 1, page 27, each of the SNPs are located in distinct sequences.

The claims further encompass many subcombinations which are disclosed as usable together in a single combination and which are also separately usable. For example, consider the following combinations of "one or more" polymorphisms selected from those in claim 7:

Subcombination (A): the polymorphisms T2303723C and C18679T

Subcombination (B): the polymorphisms G19524A and T22242A

Combination (A+B): the polymorphisms T2303723C, C18679T, G19524A and T22242A

Each of the combinations of SNPs are related as subcombinations disclosed as usable together in a single combination. The subcombinations are distinct if they do not overlap in scope and are not obvious variants, and if it is shown that at least one subcombination is

separately usable. In this case subcombinations (A) and (B) do not overlap in scope and there is no evidence on the record to suggest that they are obvious variants of one another. The subcombinations are separately usable as evidenced by their presentation in the alternative within the claims. Further, subcombination "A" has separate utility such as detecting the SNP, as a marker, or for linkage studies, for examples. So, subcombinations (A) and (B) are distinct. See MPEP § 806.05(d).

These subcombinations are also distinct from the combination which comprises them because the combination does not require the particulars of the subcombination as claimed to show novelty or unobviousness and the subcombinations have utility by themselves or in another combination. The fact that the claim encompasses an embodiment which relies on only subcombination (B) is evidence that the details of subcombination (A) are not required for patentability of the combination (A+B), and likewise, the fact that the claim encompasses an embodiment which relies on only subcombination (A) is evidence that the details of subcombination (B) are not required for patentability of subcombination (A+B). The fact that the claim encompasses embodiments which use only subcombination (A) or subcombination (B) is evidence that the subcombinations have utility by themselves.

This example particularly discusses only the combinations (A), (B) and (A+B), but the same analysis could be applied to each of the different subcombinations and combinations set forth in the instant claims.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the

Page 5

Application/Control Number: 10/552,641

Art Unit: 1634

inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Each polymorphisms must be searched by a separate query of the electronic databases. See MPEP 808.02(C). Therefore, a search for methods which use each polymorphism or each combination of polymorphism is not co-extensive with methods which use each other SNP or each other combination of polymorphism, and subsequently, the search and examination for every polymorphisms and every combination of polymorphism poses an enormous and serious burden on the examiner.

Applicant is required to select a single invention, ie, a single polymorphism or a single combination of polymorphism required for the claimed method. The invention may be a single polymorphism, a combination of more than one polymorphism but less than all of the disclosed polymorphism or a combination of all possible claimed polymorphisms. However, an election of a single invention, ie, a single polymorphism or a single combination of polymorphisms is required. This restriction requirement is predicated on the fact that the methods which use different polymorphisms or different combinations of polymorphisms do not appear obvious over one another. Should applicant traverse on the ground that the different polymorphism or different combinations of polymorphisms are not patentably distinct over each other, applicant should submit evident or identify such evidence now of record showing the inventions to be obvious variant over each other or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other inventions.

Applicant is also required to identify which claims read upon the elected invention.

The examiner has required restriction between subcombinations usable together. Where applicant elects a subcombination and claims thereto are subsequently found allowable, any claim(s) depending from or otherwise requiring all the limitations of the allowable subcombination will be examined for patentability in accordance with 37 CFR 1.104. See MPEP § 821.04(a). Applicant is advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application.

3. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarae Bausch whose telephone number is (571) 272-2912. The examiner can normally be reached on M-F 9am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on (571) 272-0735. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at (866) 217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Sarae Bausch, PhD. Examiner Art Unit 1634